Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type
Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type
复制标题
DOI：
10.1200/jco.2000.18.6.1324
复制
发表时间：
2000-03-01
影响因子：
45.3
通讯作者：
Cvitkovic, E
中科院分区：
文献类型：
--
作者：
Fandi, A;Bachouchi, M;Cvitkovic, E
目的：为了审查发病率和分析配置文件的长期完全反应者与未分化癌的鼻咽型（UCNT）治疗在一个单一的institution.Patients和方法：我们提出了一个队列的20个长期未维持的完全反应者化疗转移性UCNT治疗的研究所古斯塔夫pathisy 1978年4月至1996年11月之间。如果患者在化疗获得完全缓解后无病超过36个月，则认为患者是长期存活者。患者特征如下：性别，17名男性和3名女性;中位年龄，28岁（范围，9至62岁）;中位世界卫生组织体能状态，1;和初始肿瘤淋巴结转移阶段（国际抗癌联盟-美国癌症联合委员会，1987）T3至T4，60%，N2 b至N3，75%。EB病毒血清学特征19例。在16例预治疗患者中，11例仅接受放疗，5例接受化疗和放疗。13名患者发生局部控制的UCNT转移复发，15名患者的肿瘤部位为骨，4名患者为肺，2名患者为肝（活检证实）。化疗包括：5例患者接受顺铂、博来霉素和氟尿嘧啶; 7例患者接受博来霉素、表阿霉素和顺铂; 4例患者接受氟尿嘧啶、丝裂霉素、表阿霉素和顺铂; 1例患者接受氟尿嘧啶、博来霉素、表阿霉素和顺铂。1985年以前，3例患者接受了以铂类为基础的方案治疗。患者接受了中位6个周期（范围，3至13）。13例骨转移瘤患者接受了巩固放疗。截至1999年6月，20名患者中有14人仍然活着，治疗后没有疾病迹象（无病生存时间，82+至190+个月），3例患者在治疗后61、109和208个月完全缓解时死于其他原因，3例患者在42个月时死于疾病，治疗后89个月和115个月。长期的完全反应，在骨和内脏diseases.Conclusion：我们的数据支持化疗在转移性UCNT的治疗作用，是一个主要的激励继续研究更好的组合，以增加转移性UCNT的患者谁达到完全反应和长期生存的百分比。(C)2000年，美国临床肿瘤学会。
Purpose: To review incidence and analyze profile of long-term complete responders among patients with undifferentiated carcinoma of nasopharyngeal type (UCNT) treated at a single institution.Patients and Methods: We present a cohort of 20 long-term unmaintained complete responders to chemotherapy for metastatic UCNT treated at the Institut Gustave Roussy between April 1978 and November 1996. A patient was considered a lang-term survivor if he or she was disease-free for more than 36, months without treatment after obtaining a complete response by chemotherapy. Patient characteristics were as fallows: sex, 17 men and three women; median age, 28 years (range, 9 to 62 years); median World Health Organization performance status, 1; and initial tumor-node-metastasis stage (International Union Against Cancer-American Joint Committee on Cancer, 1987) of T3 to T4, 60%, and of N2b to N3, 75%. Epstein-Barr virus serology was characteristic in 19 patients. Of 16 pretreated patients, 11 were pretreated by radiotherapy alone and five by chemotherapy and radiotherapy. Thirteen patients herd metastatic relapses of locally controlled UCNT, Tumor sites were bone in 15 patients, lung in four, and liver (biopsy-proven) in two. Chemotherapy included the following: cisplatin, bleomycin, and fluorouracil in five patients; bleomycin, epirubicin, and cisplatin in seven patients; fluorouracil, mitomycin, epirubicin, and cisplatin in four patients and fluorouracil, bleomycin, epirubicin, and cisplatin In one patient. Three patients were treated with platinum-based regimens before 1985. Patients received a median of six cycles (range, three to 13). Thirteen patients with bone metastases received consolidating radiotherapy.Results: As of June 1999, 14 of 20 patients were still alive with no evidence of disease after treatment (disease-free survival time, 82+ to 190+ months), three patients died of other causes while in complete response at 61, 109, and 208 months after treatment, and three patients died of disease at 42, 89, and 115 months after treatment. long-term complete responses were obtained in both bone and visceral disease.Conclusion: Our data support a curative role for chemotherapy in metastatic UCNT and are a major incentive to continue research for better combinations to increase the percentage of patients with metastatic UCNT who attain complete responses and long-term survival. (C) 2000 by American Society of Clinical Oncology.